Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Apr 17, 2015
Insider Transaction Report
Form 4
Mirovsky Pavel
President of Valeant Europe
Transactions
- Exercise/Conversion
Common Stock, no par value
2015-04-15+24,175→ 34,175 total - Exercise/Conversion
Restricted Share Units
2015-04-15−24,175→ 24,175 total→ Common Stock (48,350 underlying)
Footnotes (2)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $108.97 starting on January 9, 2014 and the average stock price for the 20 trading days starting on each measurement dates: 25% on October 9, 2016, 50% on January 9, 2017 and 25% on April 9, 2017. Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout two times grant value.
- [F2]Represents the maximum number of Common Shares that may be issued under the RSU award.